Genmab A (GMAB) Short term Debt (2019 - 2025)

Genmab A (GMAB) reported Short term Debt of $273.0 million for Q4 2025, up 1850.0% quarter-over-quarter from $14.0 million in Q1 2025.

Genmab A (GMAB) Short term Debt (2019 - 2025) Analysis & Trends

Genmab A has reported Short term Debt for 3 years, with the latest figure at $273.0 million in Q4 2025.

For the quarter ending Q4 2025, Short term Debt changed N/A year-over-year to $273.0 million; the trailing twelve-month figure through Dec 2025 stood at $273.0 million (changed N/A YoY), and the FY2025 full-year result was $273.0 million, changed N/A from the prior year.
Short term Debt for Q4 2025 stood at $273.0 million, up from $14.0 million in the prior quarter.
The five-year high for Short term Debt was $273.0 million in Q4 2025, with the low at $14.0 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Genmab A	48.34 Bn	46.82 Bn	831.00 Mn

Download Data